ClinicalTrials.gg
RecruitingNCT07677072LUMINOSUpdated Jun 30, 2026

Can Serum Lumican Level Identify a Hidden Fragility Phenotype Beyond Bone Mineral Density in Postmenopausal Women?

An observational study in Osteoporosis, Postmenopausal Osteoporosis and Frailty, sponsored by Kanuni Sultan Suleyman Training and Research Hospital. Recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2026-06-30.

Primary conditionOsteoporosis, PostmenopausalRegistry: OsteoporosisReclassifiedWhy we changed it
Registry
Osteoporosis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Osteoporosis, Postmenopausal
Why
  1. The study's listed conditions name Osteoporosis, Postmenopausal, a narrower term within Osteoporosis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Kanuni Sultan Suleyman Training and Research Hospital · Observational

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
98
Ages
45 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 20 studies in Osteoporosis, Postmenopausal with a site in Turkey — 4 open to participants now, 5 under way, none of them phase 3. Osteoporosis, Postmenopausal · Turkey.

Started
2026
the only one that year
Observational
9 of 20
2 open now
Registered
19th of 20
by date
Lead sponsor
2 of 20
Kanuni Sultan Suleyman Training and Research Hospital

Among the 20 studies in Osteoporosis, Postmenopausal with a site in Turkey, this one is the only one that started in 2026, is one of 9 observational ones, and was the 19th registered.

Osteoporosis, Postmenopausal

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

Browse Osteoporosis, Postmenopausal studies →

Open to participants now

4 of the 20 studies in Osteoporosis, Postmenopausal with a site in Turkey are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 20 Osteoporosis, Postmenopausal studies recruiting now, 8 (40%) set no upper age limit and 8 (40%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 45 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Osteoporosis, Postmenopausal with a site in Turkey, or all of them as a file.
02

Study summary

Osteoporosis is a major cause of morbidity and fragility fractures in postmenopausal women. Bone mineral density (BMD) alone may not fully reflect fracture risk and skeletal fragility. Lumican, an extracellular matrix proteoglycan involved in collagen organization and musculoskeletal tissue homeostasis, has emerged as a potential biomarker for bone health. This prospective observational study aims to investigate the relationship between serum lumican levels, bone mineral density, muscle strength, and clinical fragility indicators in postmenopausal women. Approximately 100 participants will undergo routine osteoporosis assessment including DEXA, laboratory testing, FRAX evaluation, and handgrip strength measurement. The study will evaluate whether serum lumican levels can identify a hidden fragility phenotype beyond conventional bone mineral density measurements.

Read the detailed description

This is a prospective, observational, single-center clinical study designed to evaluate serum lumican levels in postmenopausal women undergoing routine osteoporosis assessment. The study will investigate the association of lumican with bone mineral density, handgrip strength, FRAX-based fracture risk, history of falls, and fragility fracture history. No treatment or interventional procedure will be applied. Serum lumican will be measured from venous blood samples, and all other clinical and laboratory data will be collected as part of standard osteoporosis evaluation. The study aims to explore whether lumican may contribute to the identification of fragility risk beyond conventional bone mineral density measurements.

03

Conditions studied

  • Osteoporosis
  • Postmenopausal Osteoporosis
  • Frailty
  • Fragility Fractures

Browse trials for

Keywords

  • Lumican
  • Osteoporosis
  • Fragility
  • FRAX
04

In context

Osteoporosis, Postmenopausal Reclassified

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

This study's planned enrollment of 98 is below the median of 160 across 57 observational studies indexed under Osteoporosis, Postmenopausal.

Browse Osteoporosis, Postmenopausal studies →

Lead sponsor

Kanuni Sultan Suleyman Training and Research Hospital is the lead sponsor of 225 studies on the registry; 35 are open to participants now.

Compared within Osteoporosis, Postmenopausal, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Osteoporosis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
45 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of postmenopausal women aged 45 years and older who attend the Physical Medicine and Rehabilitation outpatient clinic and undergo routine osteoporosis evaluation, including bone mineral density measurement by DEXA and standard osteoporosis laboratory testing. Participants will be recruited consecutively and enrolled after providing written informed consent.

Eligibility criteria

Inclusion Criteria:

Inclusion Criteria:

  • Female sex
  • Age 45 years or older
  • status
  • Attendance at the Physical Medicine and Rehabilitation outpatient clinic
  • Undergoing routine bone mineral density (DEXA) assessment and osteoporosis laboratory evaluation
  • Ability and willingness to provide written

Exclusion Criteria:

Exclusion Criteria:

  • Premenopausal women
  • Secondary causes of osteoporosis (e.g., , advanced renal failure, severe liver disease, significant endocrine disorders)
  • Active infection or acute inflammatory disease
  • Major surgery within the previous 6 months
  • Neurological or muscular disorders that may significantly affect muscle function
  • Inability to comply with study procedures and assessments
  • Current treatment with medications that significantly affect bone metabolism, including bisphosphonates, denosumab, teriparatide, or other anti-osteoporotic agents
  • Refusal or inability to provide written informed consent
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
98 participants (estimated)
Patient registry
No

Groups and cohorts

  • Postmenopausal Women Undergoing Osteoporosis Evaluation

    Postmenopausal women undergoing routine osteoporosis assessment will be included in this observational cohort. Participants will undergo bone mineral density measurement, routine osteoporosis laboratory evaluation, FRAX assessment, handgrip strength measurement, and serum lumican analysis. No treatment or interventional procedure will be administered as part of the study.

07

What researchers measure

Primary outcomes

  1. Serum Lumican Level and Bone Mineral Density Association

    Assessment of the relationship between serum lumican levels and bone mineral density (lumbar spine, total hip, and femoral neck BMD measured by DEXA).

    Time frame: Baseline (at study enrollment)

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared because no formal data-sharing plan has been established. Participant confidentiality and privacy will be protected in accordance with institutional and ethical requirements.

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Dec 2026, 6 months after the start.

Of 23 observational studies under Osteoporosis, Postmenopausal, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 65. This study's planned 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2026
First posted
Jun 30, 2026
StartActual
May 15, 2026
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Jun 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07677072
Responsible party
Dilek ün oguzhanasilturk (Physical Medicine and Rehabilitation Specialist, Kanuni Sultan Suleyman Training and Research Hospital) — Principal investigator
First posted
Jun 30, 2026
Start date
May 15, 2026
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Jun 30, 2026

Study contacts

Dilek Ün Oğuzhanasiltürk, MD
Contact
dilekunoguzhan@gmail.com
+90 5056367184
Dilek Ün oguzhanasiltürk, MD
principal investigator · Kanuni Sultan and Süleyman Training Resarch Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion